Inventiva (IVA) Income from Continuing Operations (2019 - 2025)
Inventiva (IVA) posted quarterly Income from Continuing Operations of 880664.64 for Q2 2025, up 1268.27% year-over-year from 64363.5 in Q2 2024, and up 1277.33% quarter-over-quarter from 74801.68 in Q4 2024.
Inventiva (IVA) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Inventiva's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 880664.64 for Q2 2025.
- In Q2 2025, Income from Continuing Operations rose 1268.27% year-over-year to 880664.64; the TTM figure through Jun 2025 stood at 485166.53 (up 171.52% YoY), while the FY2025 annual figure was 411824626.98, down 100523.69% from the prior year.
- Income from Continuing Operations for Q2 2025 stood at 880664.64, up from 74801.68 in the prior quarter.
- The five-year high for Income from Continuing Operations was 880664.64 in Q2 2025, with the low at 11886159.08 in Q2 2021.
- The 5-year median for Income from Continuing Operations is 178852.68 (2022), against an average of 2024253.51.
- The sharpest annual moves came in 2021 and 2025: Income from Continuing Operations retreated 22.57% in 2021, then jumped 1268.27% in 2025.
- Inventiva's Income from Continuing Operations stood at 11886159.08 in 2021, then surged by 98.03% to 234656.89 in 2022, then retreated by 4.54% to 245314.3 in 2023, then jumped by 69.51% to 74801.68 in 2024, then surged by 1277.33% to 880664.64 in 2025.
- Business Quant data shows IVA's Income from Continuing Operations at 880664.64 in Q2 2025, 74801.68 in Q4 2024, and 75382.13 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Inventiva | 888.89 Mn | 888.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 880,664.64 |
| Dec 31, 2024 | -74,801.68 |
| Jun 30, 2024 | -75,382.13 |
| Dec 31, 2023 | -245,314.30 |
| Jun 30, 2023 | -123,048.46 |
| Dec 31, 2022 | -234,656.89 |
| Jun 30, 2021 | -11.89 Mn |
| Mar 31, 2021 | -4.44 Mn |
| Dec 31, 2020 | -35.45 Mn |
| Jun 30, 2020 | -9.70 Mn |
| Mar 31, 2020 | -7.48 Mn |
| Dec 31, 2019 | -33.34 Mn |